{"id":12634,"date":"2026-07-22T20:43:26","date_gmt":"2026-07-22T10:43:26","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/?p=12634"},"modified":"2026-07-22T20:48:36","modified_gmt":"2026-07-22T10:48:36","slug":"alcohol-related-liver-disease-is-climbing-fast-treatment-alone-wont-fix-it","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/alcohol-related-liver-disease-is-climbing-fast-treatment-alone-wont-fix-it\/","title":{"rendered":"Alcohol-Related Liver Disease Is Climbing Fast. Treatment Alone Won\u2019t Fix It"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alcohol-related liver disease is climbing fast. In the United States, the death rate nearly doubled between 1999 and 2022, rising from 6.7 to 12.5 per 100,000 people. Researchers linked more than 436,000 deaths to this trend. Between 2018 and 2022, the death rate climbed by almost 9% a year.<\/p>

\"\"A 2026 JAMA review by liver specialists from Denmark, Finland and the United States confirms this pattern. Worldwide, alcohol use causes an estimated 2.6 million premature deaths every year. That\u2019s nearly 5% of all deaths on the planet.<\/p>

Who Is Most at Risk<\/strong><\/p>

The recent surge hits some groups harder than others. Adults aged 25 to 44 show the steepest rise, with deaths climbing nearly 18% a year between 2018 and 2022. Women are catching up to men too. Their mortality rate has been rising by roughly 4% a year, compared with 2.5% for men.<\/p>

American Indian and Alaska Native communities face the highest burden. Their death rate nearly doubled, moving from about 25 to almost 47 per 100,000. The COVID-19 pandemic likely made things worse. Isolation, financial strain and disrupted healthcare access left a lasting mark on drinking habits that hasn\u2019t fully faded.<\/p>

A Disease That Hides in Plain Sight<\/strong><\/p>

Alcohol-related liver disease often causes no symptoms for years. About 90% of people with the condition feel fine, or just tired, until the disease has already advanced. Hospital data backs this up.<\/p>

A nine-year study of Queensland hospitals tracked cirrhosis admissions from 2008 to 2016. Admissions jumped 62%, from 2,701 cases to 4,367. Alcohol caused 55% of them. Princess Alexandra Hospital hepatologist Elizabeth Powell called these numbers only the surface of a much bigger problem, since early cirrhosis rarely produces warning signs.<\/p>

Powell also pointed to a growing overlap with obesity and type 2 diabetes. Fatty liver disease increasingly travels alongside the broader metabolic syndrome epidemic. Doctors now need to screen for heavy drinking even in patients who show up with diabetes or obesity, not just those who admit to drinking heavily.<\/p>

Warning Signs Come Too Late<\/strong><\/p>

When symptoms finally appear, they include jaundice, abdominal swelling, nausea, appetite loss and swelling in the legs. By then, the disease has usually reached a harder-to-reverse stage.<\/p>

Delayed diagnosis is common. A Danish registry study found that 40% of people eventually diagnosed with alcohol-related cirrhosis had already visited a hospital for an alcohol-related problem beforehand. Fifteen percent had five or more such visits. The warning signs were there. Doctors simply missed them.<\/p>

What Helps Once Someone Is Diagnosed<\/strong><\/p>

Stopping alcohol use remains the single most powerful treatment. Researchers followed people with alcohol-related cirrhosis for a median of three years. Those who quit drinking cut their risk of dying from liver disease by more than half. Their overall mortality risk dropped similarly. Early-stage fatty liver can fully reverse within weeks of quitting.<\/p>

Testing itself seems to change behaviour. Researchers gave one group of 1,850 Danish adults a liver stiffness test. Excessive drinking in that group fell from 46% to 32% within six months. A UK trial found similar results: patients who saw their own fibrosis test results were far more likely to cut back or quit than those who didn\u2019t.<\/p>

Medication plays a smaller role. Only baclofen showed a clear benefit in randomized trials among people with alcohol-related cirrhosis. No medication currently treats the liver disease itself.<\/p>

Why Liver Disease Prevention Beats Screening Alone<\/strong><\/p>

Screening, testing and treatment all work after someone already drinks at harmful levels. That\u2019s useful, but it\u2019s also late. A commentary in the International Journal of Mental Health and Addiction argues this is the real structural problem. Treatment and harm-reduction services rarely connect with the prevention and regulation efforts that could stop harmful drinking before it starts.<\/p>

The two systems tend to operate on separate tracks. Prevention researchers design programs to reduce future harm. Treatment providers respond to harm that\u2019s already occurred. Few systems link the two together, and that gap shows up in the numbers above.<\/p>

Australia\u2019s Policy Shift Offers a Blueprint<\/strong><\/p>

Australia offers a useful case study. Through the 1990s, Australian schools relied heavily on harm-reduction drug education. The reasoning went that adolescents would drink regardless, so the goal was simply to reduce the harm from it. Australian teenagers ended up drinking and using drugs at much higher rates than similar American teens, whose schools taught abstinence-focused programs instead.<\/p>

In 2009, Australian guidelines shifted. They began recommending that adolescents avoid alcohol entirely until age 18. School programs followed suit. One trial found that parent-focused education cut heavy adolescent drinking by 25%. Those gains carried forward. Young adults who grew up under the new guidelines now drink less than earlier generations did.<\/p>

Programs and Policies With Proven Results<\/strong><\/p>

Support for abstinence-based approaches doesn\u2019t stop at adolescence. A Cochrane review of Alcoholics Anonymous and Twelve-Step Facilitated treatment found these programs beat standard therapies like CBT at sustaining long-term abstinence. Continuous abstinence rates improved by 21% at twelve months, and the advantage held at two and three years.<\/p>

Yet few people use these programs. Only 0.1% of Australian adults have ever attended an AA meeting, compared with 0.5% in the United States. That gap suggests real room to grow.<\/p>

Community-based prevention also works. The Communities That Care model helps local coalitions target risk factors before they turn into harm. Australian towns using this model saw drops in adolescent drinking, youth crime and hospital-admitted injuries. One US trial found that communities earned nearly $13 back for every dollar they spent.<\/p>

Regulation matters too. When Scotland and Ireland set a minimum price per unit of alcohol in 2018, alcohol-related deaths fell by about 12% over the next three years. Alcohol-related hospital admissions dropped by roughly 10% over the same period.<\/p>

Closing the Prevention Gap<\/strong><\/p>

None of this means treatment and harm reduction should disappear. Needle exchanges, road-safety testing and medication-assisted treatment all still matter for people living with alcohol use disorder today.<\/p>

But liver specialists, addiction researchers and hospital data all point to the same conclusion. A largely preventable disease keeps showing up in emergency rooms, in advancing cirrhosis, and in death rates climbing fastest among the young, long after the damage happens. Real progress means treating prevention, regulation and recovery as one connected system, not three separate ones. Effective liver disease prevention, not late-stage screening, deserves to sit at the centre of that system.<\/p>

Sources:<\/p>